Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

摘要: Summary Purpose Epidermal growth factor receptor (EGFR) mutations have been found in the majority of gefitinib-responsive non-small cell lung cancer (NSCLC) patients from retrospective studies. We sought to compile available phase II and prospective trials this EGFR tyrosine kinase inhibitor (TKI) better understand efficacy safety selecting receive gefitinib based on their genotype. Design searched published involving EGFR-mutant gefitinib. Five reports were identified (published between June 2006 April 2007) which was given a manner mutation positive at dose 250 mg/day. Responses determined by RECIST toxicities NCI-CTC. Results A total 101 pooled these Fifty-nine received as first line therapy 42 after having chemotherapy. The combined rate complete partial response (CR + PR) 99 measured 80.8% (80/99) only 7.1% (7/99) had progressive disease best response. for exon 19 deletion L858R 80.3% (53/66) 81.8% (27/33), respectively. median progression-free survival ranged 7.7 12.9 months. Overall not reached 4/5 15.4 months one them. Gefitinib administration safe ( Conclusions monotherapy leads objective responses most with mutations. Both derived similar clinical benefits. Small molecule TKIs are new treatment paradigm NSCLC.